Human Longevity, Inc. (HLI) to Offer Oncology Products Including Comprehensive Whole Germline …

SAN DIEGO, Jan. 12, 2016 /PRNewswire/ — Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, announced today its oncology genomics program, including the development of comprehensive whole germline and tumor genome analysis, as well as tumor and germline exome analysis products. “As part of HLI’s mission to tackle some of the most troubling diseases that limit our healthy lifespans, we have obviously been focused on cancer. There is a strong need for a new and cost-effective cancer genome product because most insurance companies aren’t generally covering these kinds of tests. We believe our science and technology should offer more informed treatment options for a large number of patients and their physicians,” said J. Craig Venter, Ph.D., Co-founder and CEO, HLI. With HLI’s comprehensive whole germline and cancer genome product, a patient’s germline…


Link to Full Article: Human Longevity, Inc. (HLI) to Offer Oncology Products Including Comprehensive Whole Germline …